Microgrewiapine A acts as an antagonist of nicotinic acetylcholine receptors (nAChRs); it inhibits the activity of hα4β2 and hα3β4 nAChR subtypes with 60% and 70% inhibition, respectively; it exhibits selective cytotoxicity against HT-29 human colon cancer cells with an IC50 of 6.8 μM.